Developer docs
API playgroundTry for free, no card

Search company profiles

Pulmovant

Full company profile

uuid0033ua2

Namestring
Pulmovant
Legal namestring
Pulmovant, Inc.
Websiteurl
pulmovant.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Pulmovant is a clinical-stage biotechnology company founded in 2023 as a wholly-owned subsidiary of Roivant Sciences (NASDAQ: ROIV), singularly focused on developing therapies for pulmonary diseases. The company is headquartered in Waltham, Massachusetts, operates with 11–50 employees, and is led by a management team with deep inhaled-drug-development credentials drawn from AstraZeneca, Acceleron, Eli Lilly, Actelion, and Idorsia. Its lead and only clinical asset is mosliciguat (BAY 1237592), a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a WHO Group 3 condition affecting up to 200,000 patients in the US and Europe with limited approved treatment options.

Mosliciguat's mechanism is differentiated from existing sGC stimulators in that it acts independently of heme and nitric oxide, preserving enzymatic activity in the oxidative environments characteristic of PH-ILD. The compound is formulated for delivery via a low-resistance dry powder inhaler (DPI) requiring only a single inhalation per day, contrasting with multiple-dose nebulized or multi-inhalation inhaled PH therapies. Clinical progress to date includes a Phase 1 program spanning 170 participants showing favorable safety, dose-dependent cGMP increases, and a 40-hour half-life; a Phase 1b ATMOS study in 38 PH patients demonstrating mean peak PVR reductions of up to 38%; and two ongoing Phase 2 trials — the global PHocus monotherapy study (NCT06635850, ~120 participants, enrollment completed in under 12 months) and the PHactor combination study with inhaled treprostinil.

Pulmovant is pre-revenue and operates a pre-commercial business model: capital is sourced through its Roivant parent, and future revenue is expected to come from pharmaceutical product sales following regulatory approval. The company received Japan MHLW orphan drug designation for mosliciguat in September 2025, providing up to 10 years of post-approval market exclusivity. Anticipated go-to-market relies on specialty pharmacy networks and hospital-based field sales targeting PH specialists and pulmonologists across the US and EU, with topline Phase 2 data expected in the second half of calendar year 2026 as the next value-defining catalyst.

Short descriptiontext

Pulmovant is a clinical-stage biotechnology subsidiary of Roivant Sciences developing mosliciguat, a potential first-in-class once-daily inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulmonary hypertension therapies, respiratory disease treatments, inhaled drug delivery, clinical-stage biotechnology, orphan drug development
Industry3 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pulmonary Hypertension Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage biotech, Pulmovant is pre-revenue. The company is developing mosliciguat for PH-ILD, a rare disease indication with orphan drug designation. Future revenue will come from pharmaceutical product sales upon regulatory approval. PH-ILD affects up to 200,000 patients in U.S. and Europe with limited to no approved treatment options, representing an attractive commercial opportunity.

pulmovant.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pulmovant is a clinical-stage biotechnology company developing mosliciguat (BAY 1237592), a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug is delivered via a low-resistance dry powder inhaler requiring a single inhalation per day, with a differentiated mechanism of action that functions independently of heme and nitric oxide. The company is running the Phase 2 PHocus monotherapy trial and the Phase 2 PHactor combination trial with inhaled treprostinil, and holds orphan drug designation in Japan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Mean peak PVR reduction of up to 38% in Phase 1b ATMOS study - one of the highest reductions seen in PH trials to date
+4 more records
Product overview1 text field

Pulmovant is a clinical-stage biotechnology company developing a single investigational product, mosliciguat, for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator delivered via dry powder inhaler. The company's development pipeline includes the Phase 2 PHocus study for monotherapy and the Phase 2 PHactor study for combination therapy with inhaled treprostinil. The product completed Phase 1b ATMOS proof-of-concept study demonstrating up to 38% reduction in pulmonary vascular resistance.

Product and service1 record
1Mosliciguat (BAY 1237592)
CategoryPulmonary Hypertension Therapeutics
Description

Mosliciguat (BAY 1237592) is a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator designed for targeted pulmonary vasodilation with limited systemic side effects in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is delivered via a low-resistance dry powder inhaler as a lactose carrier-based formulation requiring only a single inhalation per day.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

Gossamer Bio is developing seralutinib, an inhaled kinase inhibitor for PAH and PH-ILD. While mechanism-distinct (tyrosine kinase vs sGC activator), Gossamer targets the same inhaled PH-ILD niche and represents another late-stage competitive entrant.

TypeDirect peer
Description

Liquidia is a PH-focused biopharmaceutical company with an inhaled treprostinil program (YUTREPIA) targeting PAH and PH-ILD. It competes for the same physician-prescriber base and specialty distribution channel that Pulmovant plans to enter.

TypeBroad incumbent
Description

United Therapeutics markets Tyvaso DPI (inhaled treprostinil), which is FDA-approved for PH-ILD and serves as the on-market benchmark Pulmovant must displace. UTHR is a well-capitalized incumbent with established physician relationships across the PH specialist community.

TypeBroad incumbent
Description

Bayer developed and markets Adempas (riociguat), a systemic sGC stimulator approved for PAH and CTEPH. Bayer also originally developed mosliciguat before it was licensed into Pulmovant, making it both the originator of the compound and the established sGC-modulation reference product.

5Johnson & Johnson (Actelion)
TypeBroad incumbent
Description

J&J's Actelion franchise markets Opsumit, Tracleer, and Uptravi — the foundational PAH and CTEPH therapies that Pulmovant leadership (e.g., Amy Yoney, Brian Schlag) previously worked on. The franchise defines physician algorithms Pulmovant will position mosliciguat against.

TypeEmerging player
Description

Altavant is a Roivant-affiliated Vant focused on rare pulmonary diseases, including PH-ILD. It is the closest sibling company within the Roivant portfolio and is structured similarly as a thinly-resourced, single-asset clinical-stage biotech targeting pulmonary hypertension indications.

TypeDirect peer
Description

Aerovate Therapeutics is developing an inhaled dry powder formulation of imatinib for PH-ILD. It is the most direct competitor to Pulmovant's mosliciguat, addressing the same patient population with an inhaled lung-targeted approach and competing for the same specialty pharmacy channel.

TypeBroad incumbent
Description

Insmed is a specialty biopharma company with a respiratory franchise (Arikayce for nontuberculous mycobacterial lung disease) and is advancing pulmonary programs. It represents a comparable specialty-pulmonary commercial infrastructure against which Pulmovant's eventual go-to-market will be benchmarked.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pulmovant

Pulmonary Hypertension Therapeuticspulmovant.com

Pulmovant is a clinical-stage biotechnology subsidiary of Roivant Sciences developing mosliciguat, a potential first-in-class once-daily inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What Pulmovant does

Pulmovant is a clinical-stage biotechnology company founded in 2023 as a wholly-owned subsidiary of Roivant Sciences (NASDAQ: ROIV), singularly focused on developing therapies for pulmonary diseases. The company is headquartered in Waltham, Massachusetts, operates with 11–50 employees, and is led by a management team with deep inhaled-drug-development credentials drawn from AstraZeneca, Acceleron, Eli Lilly, Actelion, and Idorsia. Its lead and only clinical asset is mosliciguat (BAY 1237592), a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a WHO Group 3 condition affecting up to 200,000 patients in the US and Europe with limited approved treatment options.

Mosliciguat's mechanism is differentiated from existing sGC stimulators in that it acts independently of heme and nitric oxide, preserving enzymatic activity in the oxidative environments characteristic of PH-ILD. The compound is formulated for delivery via a low-resistance dry powder inhaler (DPI) requiring only a single inhalation per day, contrasting with multiple-dose nebulized or multi-inhalation inhaled PH therapies. Clinical progress to date includes a Phase 1 program spanning 170 participants showing favorable safety, dose-dependent cGMP increases, and a 40-hour half-life; a Phase 1b ATMOS study in 38 PH patients demonstrating mean peak PVR reductions of up to 38%; and two ongoing Phase 2 trials — the global PHocus monotherapy study (NCT06635850, ~120 participants, enrollment completed in under 12 months) and the PHactor combination study with inhaled treprostinil.

Pulmovant is pre-revenue and operates a pre-commercial business model: capital is sourced through its Roivant parent, and future revenue is expected to come from pharmaceutical product sales following regulatory approval. The company received Japan MHLW orphan drug designation for mosliciguat in September 2025, providing up to 10 years of post-approval market exclusivity. Anticipated go-to-market relies on specialty pharmacy networks and hospital-based field sales targeting PH specialists and pulmonologists across the US and EU, with topline Phase 2 data expected in the second half of calendar year 2026 as the next value-defining catalyst.

Pulmovant firmographics

Firmographics
Name
Pulmovant
Legal name
Pulmovant, Inc.
Website
https://pulmovant.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Pulmovant is a clinical-stage biotechnology subsidiary of Roivant Sciences developing mosliciguat, a potential first-in-class once-daily inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Ownership category
akta.pro rank

Pulmovant industry classification

Industry
Product category
Pulmonary Hypertension Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Pulmonary hypertension therapies
  • Respiratory disease treatments
  • Inhaled drug delivery
  • Clinical-stage biotechnology
  • Orphan drug development

Where Pulmovant is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pulmovant business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Revenue: As a clinical-stage biotech, Pulmovant is pre-revenue. The company is developing mosliciguat for PH-ILD, a rare disease indication with orphan drug designation. Future revenue will come from pharmaceutical product sales upon regulatory approval. PH-ILD affects up to 200,000 patients in U.S. and Europe with limited to no approved treatment options, representing an attractive commercial opportunity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pulmovant product offering

Product offering

Core offering

Pulmovant is a clinical-stage biotechnology company developing mosliciguat (BAY 1237592), a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug is delivered via a low-resistance dry powder inhaler requiring a single inhalation per day, with a differentiated mechanism of action that functions independently of heme and nitric oxide. The company is running the Phase 2 PHocus monotherapy trial and the Phase 2 PHactor combination trial with inhaled treprostinil, and holds orphan drug designation in Japan.

Product overview

Pulmovant is a clinical-stage biotechnology company developing a single investigational product, mosliciguat, for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator delivered via dry powder inhaler. The company's development pipeline includes the Phase 2 PHocus study for monotherapy and the Phase 2 PHactor study for combination therapy with inhaled treprostinil. The product completed Phase 1b ATMOS proof-of-concept study demonstrating up to 38% reduction in pulmonary vascular resistance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mosliciguat (BAY 1237592) Mosliciguat (BAY 1237592) is a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator designed for targeted pulmonary vasodilation with limited systemic side effects in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is delivered via a low-resistance dry powder inhaler as a lactose carrier-based formulation requiring only a single inhalation per day.

Quantifiable outcome

  • Mean peak PVR reduction of up to 38% in Phase 1b ATMOS study - one of the highest reductions seen in PH trials to date
  • +4 more outcomes

Companies that use Pulmovant

Customer profile

Segments1 record

Ideal customer profiles2 records

Pulmovant technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pulmovant partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Pulmovant competitors and assessment

Company assessment

Emerging players

  • Gossamer Bio: Gossamer Bio is developing seralutinib, an inhaled kinase inhibitor for PAH and PH-ILD. While mechanism-distinct (tyrosine kinase vs sGC activator), Gossamer targets the same inhaled PH-ILD niche and represents another late-stage competitive entrant.
  • Altavant Sciences: Altavant is a Roivant-affiliated Vant focused on rare pulmonary diseases, including PH-ILD. It is the closest sibling company within the Roivant portfolio and is structured similarly as a thinly-resourced, single-asset clinical-stage biotech targeting pulmonary hypertension indications.

Direct peers

  • Liquidia Corporation: Liquidia is a PH-focused biopharmaceutical company with an inhaled treprostinil program (YUTREPIA) targeting PAH and PH-ILD. It competes for the same physician-prescriber base and specialty distribution channel that Pulmovant plans to enter.
  • Aerovate Therapeutics: Aerovate Therapeutics is developing an inhaled dry powder formulation of imatinib for PH-ILD. It is the most direct competitor to Pulmovant's mosliciguat, addressing the same patient population with an inhaled lung-targeted approach and competing for the same specialty pharmacy channel.

Broad incumbents

  • United Therapeutics: United Therapeutics markets Tyvaso DPI (inhaled treprostinil), which is FDA-approved for PH-ILD and serves as the on-market benchmark Pulmovant must displace. UTHR is a well-capitalized incumbent with established physician relationships across the PH specialist community.
  • Bayer (Adempas/riociguat): Bayer developed and markets Adempas (riociguat), a systemic sGC stimulator approved for PAH and CTEPH. Bayer also originally developed mosliciguat before it was licensed into Pulmovant, making it both the originator of the compound and the established sGC-modulation reference product.
  • Johnson & Johnson (Actelion): J&J's Actelion franchise markets Opsumit, Tracleer, and Uptravi — the foundational PAH and CTEPH therapies that Pulmovant leadership (e.g., Amy Yoney, Brian Schlag) previously worked on. The franchise defines physician algorithms Pulmovant will position mosliciguat against.
  • Insmed Incorporated: Insmed is a specialty biopharma company with a respiratory franchise (Arikayce for nontuberculous mycobacterial lung disease) and is advancing pulmonary programs. It represents a comparable specialty-pulmonary commercial infrastructure against which Pulmovant's eventual go-to-market will be benchmarked.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Pulmovant compliance and trust

Trust signal

Compliance1 record

Pulmovant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pulmovant leadership team

Management profile

Number of profiles

Profiles11 records

Pulmovant funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pulmovant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulmovant

What does Pulmovant do?

Pulmovant is a clinical-stage biotechnology company developing mosliciguat (BAY 1237592), a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug is delivered via a low-resistance dry powder inhaler requiring a single inhalation per day, with a differentiated mechanism of action that functions independently of heme and nitric oxide. The company is running the Phase 2 PHocus monotherapy trial and the Phase 2 PHactor combination trial with inhaled treprostinil, and holds orphan drug designation in Japan.

Is Pulmovant a public or private company?

Pulmovant is a private company. It is classified as corporate owned and is currently operating.

When was Pulmovant founded?

Pulmovant was founded in 2023. It employs 51 to 100 people.

Where is Pulmovant based?

Pulmovant is headquartered in Waltham, United States, in the North America region.

How does Pulmovant make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Pulmovant's main competitors?

Emerging players on record are Gossamer Bio and Altavant Sciences. Direct peers are Liquidia Corporation and Aerovate Therapeutics. Broad incumbents are United Therapeutics, Bayer (Adempas/riociguat), Johnson & Johnson (Actelion) and Insmed Incorporated.

Does Pulmovant have an API?

No public API is recorded for Pulmovant.

What industry is Pulmovant in?

Pulmovant's product category is Pulmonary Hypertension Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FAZ.NETLungenhochdruck: Neuer Wirkstoff Mosliciguat zeigt ErfolgeResearchers at the University of Gießen developed a new drug for severe pulmonary hypertension, Mosliciguat, which is tested as an inhaled dry powder. The drug is not yet approved, and a Phase-III study with about 375 patients has begun with Pulmovant, the final step before possible approval.BeckershospitalreviewLung disease drug posts record 56.3% reduction in trial: 5 notesRoivant's mosliciguat achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of 135 patients with pulmonary hypertension and interstitial lung disease. The drug also improved six-minute walk distance by 35.2 meters and lowered NT-proBNP by 53.2%. Pulmovant has initiated the phase 3 PHrontier trial, expected to enroll about 375 patients.BioSpaceRoivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 dataRoivant's mosliciguat reduced pulmonary vascular resistance by over 56% in a Phase 2 trial, exceeding analysts' expectations and advancing to Phase 3. The drug, developed by Pulmovant, lifted Roivant's stock more than 14% in premarket trading. The company plans to enroll patients in the Phase 3 study.Investing.comPulmovant’s mosliciguat meets phase 2 trial endpoints in PH-ILD By Investing.comPulmovant's Phase 2 trial of mosliciguat met primary and secondary endpoints in PH-ILD patients, showing a 56.3% reduction in pulmonary vascular resistance at Week 16. The company has initiated a Phase 3 PHrontier study with enrollment underway.Investing.comPulmovant’s mosliciguat meets phase 2 trial endpoints in PH-ILD By Investing.comPulmovant's Phase 2 trial of mosliciguat met primary and secondary endpoints in PH-ILD patients, showing a 56.3% reduction in pulmonary vascular resistance at Week 16. The trial enrolled 135 patients across 87 sites, and the company has initiated a Phase 3 study with about 375 patients.FinancialContent Business PagePulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier SPulmovant announced positive Phase 2 results for mosliciguat in PH-ILD, showing a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16. The study also improved six-minute walk distance by 35.2 meters and reduced NT-proBNP by 53.2%. A Phase 3 PHrontier trial has been initiated with enrollment underway.Investing.comPulmovant to present phase 2 mosliciguat study results Tuesday By Investing.comPulmovant will present Phase 2 PHocus study results for mosliciguat in pulmonary hypertension with interstitial lung disease at the European Respiratory Society Congress on September 8, 2026. The randomized, double-blind, placebo-controlled trial enrolled 135 participants. The company is also evaluating mosliciguat in combination with treprostinil in the Phase 2 PHactor study.Quiver QuantitativeRoivant and Pulmovant to Present Phase 2 PHocus Study Results of Mosliciguat in PH-ILD at ERS 2026 | ROIV Stock NewsRoivant and Pulmovant will present Phase 2 PHocus study results of mosliciguat for pulmonary hypertension associated with interstitial lung disease at the ERS Congress on September 8, 2026, with Dr. Marc Humbert. Roivant will also host an investor call and webcast on the same day.Investing.comPulmovant to present phase 2 mosliciguat study results Tuesday By Investing.comPulmovant will present Phase 2 PHocus study results for mosliciguat in pulmonary hypertension with interstitial lung disease at the European Respiratory Society Congress on September 8, 2026. The randomized, double-blind, placebo-controlled trial enrolled 135 participants, and the company is also evaluating the drug in a Phase 2 PHactor study.Investing.comPulmovant to present phase 2 mosliciguat study results Tuesday By Investing.comPulmovant will present Phase 2 PHocus study results for mosliciguat in pulmonary hypertension with interstitial lung disease at the European Respiratory Society congress on September 8, 2026. The randomized, double-blind, placebo-controlled trial enrolled 135 participants. The company is also evaluating mosliciguat in combination with treprostinil in the Phase 2 PHactor study.